I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ARVO 2025

We will be contributing to topics related to
-
02:00 PM
Duration 105mins Salt Lake City, USA
Pigment Epithelial Detachment Thickness Fluctuations in the Archway Trial of the Port Delivery Platform With Ranibizumab (PDS)
Brodie F, Graff J, Lai T, Malik D, Ruiz-Medrano J, Priglinger S, Blotner S, Gordon A, Holekamp N, Prager A, Heinrich D
Duration 105mins Salt Lake City, USA
Impact of PDS Treatment in Study Eyes vs Anti-VEGF Injections in Fellow Eyes on Efficacy and Safety Outcomes in Patients With Bilateral DME in the Pagoda Trial
Wirthlin R, Eichenbaum D, Graff J, Udaondo P, Hsieh YT, Hsu J, Blotner S, Gune S, Jones M, Santhanakrishnan A, Schimpl A, Heinrich D
Duration 105mins Salt Lake City, USA
Retinal Fluid and Thickness Fluctuations in Patients With Diabetic Macular Edema: Results From the Pagoda Trial of the Port Delivery Platform With Ranibizumab (PDS)
Marcus D, Tan G, Awh C, Eter N, Hatz K, Menezes A, Eghoej M, Gordon A, Blotner S, Heinrich D
Duration 105mins Salt Lake City, USA
Sustained Suppression of Aqueous Humor Free VEGF Following Continuous Delivery via the PDS in the Pagoda and Pavilion Trials
Maass K, Gill M, Javey G, Chang M, Hsu J, Hyung S, Latkany P, Tian K
Duration 105mins Salt Lake City, USA
Volumetric Analysis of Retinal Fluids in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Sheth V, Chakravarthy U, Blotner S, Heinrich D, Neubert A, Orduna J, Yu S
07:00 PM
Duration 105mins Salt Lake City, USA
Intravitreal IL-6 Inhibition With Vamikibart in Uveitic Macular Edema (UME): Baseline Characteristics of the DOVETAIL Phase 1 Study
Meike Pauly-Evers, Hu A, Lin P, Suhler E, Zeinab Barekati, William Holmes, Laura Steeples, Zdenka Haskova, Sascha Fauser, Marina Mesquida
Duration 105mins Salt Lake City, USA
Real-World Treatment Patterns In Patients With Macular Edema (ME) Due To Noninfectious Uveitis (NIU) In The United States
Eichenbaum D, Steeples L, Mesquida M, Stoilov I, Dayal P, Kavanagh L, Haskova Z
Duration 105mins Salt Lake City, USA
Faricimab▼ Real-World Data Support Clinical Trial Data in Patients With Treatment-Naïve nAMD: Results From TENAYA/ LUCERNE and FARETINA/FARWIDE
Jay Berdia, Haug S, Avery R, Souied E, Bonine N, Chi G, Dayal P, Amador M, Kotecha A, Margaron P, Yang M
Duration 105mins Salt Lake City, USA
Baseline and Early Treatment Response Variables Associated With Faricimab▼ Durability in Treatment-Naïve nAMD: TENAYA/LUCERNE Post Hoc Analyses
Colin Tan, Gallego-Pinazo R, Koh A, Pitcher J, Dagincourt N, Hill L, Yang M, Patel S, Margaron P
09:00 PM
Duration 105mins Salt Lake City, USA
Quantitative Ultra-Widefield Fluorescein Angiography for the Assessment of Novel Biomarkers of Vascular Stability With Faricimab▼: A YOSEMITE/RHINE Post Hoc Analysis
Justis Ehlers, Matar K, Indurkar A, Della Vecchia L, Amine R, Mamone J, Tang A, Gibson K, Dagincourt N, Mar F, Amador M, Warter A, Sim D
Duration 105mins Salt Lake City, USA
Update on Faricimab▼ for DME: New Clinical Features of Eyes in the RHONE-X study
Michael Singer, Arshad Khanani, Francis Abreu, Kara Gibson, Alex Kotak, Timothy Y. Y. Lai, Ian Pearce, Patricio Schlottmann, Dawn A. Sim, Yannan Tang, Aachal Kotecha
Duration 105mins Salt Lake City, USA
Treatment Response and Safety of Faricimab▼ in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US
Joseph Coney, Amador M, Brown J, Cunningham M, Emanuelli A, Huddleston S, Milunovich S, Scott A, Yang M, Lu X-Y, Gonzalez L
Duration 105mins Salt Lake City, USA
Effectiveness and Safety of Faricimab▼ in Eyes With DME in the United Kingdom: 1-Year Results From the FARWIDE-DME Study
Tunde Peto, Sivaprasad S, Reynolds R, Bailey C, Downey L, Kiire C, Pearce I, Dayal P, James N, Rothwell A, Shah N, Downey A, Dodds M, Chi G
Duration 105mins Salt Lake City, USA
Two-Year Real- World Clinical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab▼ in the US: The FARETINA-DME Study
Singh R, Zwick E, Bonine N, Leng T, Stella K, Shaia J, Ali F, Borkar D
Duration 105mins Salt Lake City, USA
Prevalence of Retina Conditions: A Focus on Underserved Populations by Regions in the US in 2022
Ko S, Bonine N, Borkar D
09:15 PM
Duration 15mins The Calvin L. Rampton Salt Palace Convention Center
Indirect Comparison of the Relative Effectiveness of Faricimab▼ vs Aflibercept 8 mg in DME and nAMD
Eric Nudleman, Keane P, Holekamp N, Leng T, Siedlecki J, Mar F, Gibson K, Margaron P, Paulo T, Buehrer C, Tabano D
09:30 PM
Duration 15mins The Calvin L. Rampton Salt Palace Convention Center
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Junyeop Lee, Cheung G, Chen S-J, Iida T, Koh A, Lee W K, Ruamviboonsuk P, Sun X, Yanagi Y, Bai R, Margaron P, Nguyen Duc A, Lai T YY
02:30 PM
Duration 105mins Salt Lake City, USA
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With nAMD or DME From a Prospective Noninterventional Study: The VOYAGER Study
Robyn Guymer, Steffen Schmitz-Valckenberg, Clare Bailey, Voraporn Chaikitmongkol, Varun Chaudhary, Gloria Chi, Amanda Downey, Robert Finger, Adrian Koh, Susumu Ishida, Monica Lövestam-Adrian, Mariacristina Parravano, Jose Luna Pinto, Veeral Sheth, Beijue Shi, Eric Souied, Diane Uschner
Duration 105mins Salt Lake City, USA
Effectiveness and Safety of Faricimab▼ in Eyes With nAMD in the United Kingdom: 18-Month Results From the FARWIDE-nAMD Study
Deepali Varma, McKibbin M, Talks J, DeSalvo G, Patel P, DeSilva S, Gale R, Dayal P, James N, Rothwell A, Shah N, Downey A, Dodds M, Chi G
Duration 105mins Salt Lake City, USA
Two-Year Real-World Clinical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼ in the US: The FARETINA-nAMD Study
Borkar D, Zwick E, Bonine N, Leng T, Stella K, Shaia J, Ali F, and Singh R
09:30 PM
Duration 105mins Salt Lake City, USA
Volumetric Analysis of Hard Exudates on Optical Coherence Tomography: Biomarker Results of Faricimab▼ vs Aflibercept From the Phase 3 YOSEMITE/RHINE Trials
Stela Vujosevic, Andreas Pollreisz, Christiana Dinah, Roger Goldberg, Michael Ip, Ehsan Rahimy, Manuel Amador, Isabel Bachmeier, Kara Gibson, Andreas Maunz, Olivia O’Leary, Diane Uschner
Duration 105mins Salt Lake City, USA
Ultra-Responders to Faricimab▼: ≥ 4-Step Improvement in Diabetic Retinopathy Severity in YOSEMITE/RHINE
Samir Patel, Michael Klufas, Jason Hsu, Warter A, Nicholas Dagincourt, Gibson K
Duration 105mins Salt Lake City, USA
Predictors of Extended Treatment Intervals in Patients With DME Treated With Faricimab▼ in the Phase 3 YOSEMITE/RHINE Trials
Bianca Gerendas, Ambresin A, Arevalo F, Gibson K, Sim D, Hill L , Yang M
08:00 PM
Duration 105mins Salt Lake City, USA
Association of Early Macular Leakage Resolution With Extended Dosing Intervals in Patients With RVO: A BALATON/COMINO Post Hoc Analysis
Harit K Bhatt, Joern Schwitzer, Jan Thommen, Nicholas Dagincourt, Liliana Paris Pereira
02:00 PM
Duration 105mins Salt Lake City, USA
Gold Standard vs. Ultrawide Field Imaging for Diabetic Retinopathy Severity: Results from YOSEMITE/RHINE Phase 3 Studies
Domalpally A, Tang Y, Willis J, Gibson K, Khanani A, Wykoff C, Haskova Z
08:00 PM
Duration 105mins Salt Lake City, USA
Characterization of a Tailored Bi-Specific DutaFab, Zifibancimig, for Neutralizing Both VEGF-A and Ang-2, and Continuous Ocular Delivery via the Port Delivery Platform
Moelleken J, Molhoj M, Benz J, Caruso A, Fenn S, Fueth M, Monnier CA, Speck J, Ullmer C
Coming soon